Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DR7Q5N
|
|||
| Drug Name |
REGN5458
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 1/2 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell maturation protein (TNFRSF17) | Target Info | Inhibitor | [2] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | Inhibitor | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03761108) First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 2 | A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.